9 results about "Gp41" patented technology

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

The present application belongs to the field of biomedical detection technology, and particularly relates to a kit for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method, and a test strip for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method. The test strip comprises a base plate, a sample pad, a latex pad, a nitrocellulose membrane and a water absorption pad. The sample pad, the latex pad, the nitrocellulose membrane and the water absorption pad are sequentially and adjacently bonded on the base plate in a chromatographic direction. The nitrocellulose membrane is provided with a quality control line and two detection lines. The quality control line is coated with goat anti-mouse IgG. The two detection lines are respectively coated with streptavidin and HEV monoclonal antibody 2. The latex pad is coated with latex-labeled GP41, GP36, GP120 mixed antigen, GP160 antigen and HEV monoclonal antibody 1. The sample pad is coated with biotin-coupled SPA. The kit disclosed by the present application is convenient to use, simple to operate, and can simultaneously detect HIV antibodies and HEV antigens.

This application discloses an HIV antigen comprising the gp41 protein; said gp41 protein contains at least one amino acid residue selected from the following: T at position 85; K at position 98; a basic amino acid R or K at position 109; a neutral amino acid L or I at position 111; a basic amino acid K or R at position 132; N at position 133; and an acidic amino acid D or E at position 139. The HIV antigen of this application has the advantages of high specificity and high sensitivity.

The present disclosure relates to vaccine compositions against respiratory syncytial virus (RSV) that are tomato-based and their methods of production. The vaccine compositions comprise tomato fruit and plant-expressed fragment of RSV F protein, preferably the ectodomain of the RSV F protein. In some aspects, the vaccine compositions comprise tomato fruit and plant-expressed human immunodeficiency virus (HIV) virus-like particle (VLP) wherein the fragment of RSV F protein is displayed on the VLP surface. For example, the vaccine compositions are tomato paste spiked with the plant-expressed HIV VLP. In certain embodiments, the plant-expressed HIV VLP comprises a Gag protein; a fragment of gp41 protein, which comprises the C-terminal cytosolic domain of the gp41 protein; and a fragment of RSV F protein, wherein the fragment of RSV F protein lacks the p27 region and the C-terminus of the fragment of RSV F protein is linked to the N-terminus of the fragment of gp41 protein.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

To provide a multispecific antigen-binding molecule targeting HIV and a method for its use. [Solution] A multispecific antigen-binding molecule is provided, comprising a bispecific antibody that binds to CD3 containing the HIV envelope protein gp120 and to the HIV antigen. Methods of using such an antigen-binding molecule to treat or prevent HIV infection are also provided. In some embodiments, the multispecific or bispecific molecule comprises a first antigen-binding domain targeting human CD3, which is a single-chain variable fragment (scFv) fused to Fc, while a second antigen-binding domain targeting the HIV antigen (e.g., gp120 or gp41) consists of a Fab antigen-binding fragment fused to Fc.

System for detecting interactions between a first a second protein comprising: (a) a first construct comprising the first protein fused to a first handle comprising a β10 peptide or a β9 peptide of a nanoluciferase fused to the N-terminal of a modified N-terminus intein (IN) of GP41-1; and (b) a second construct comprising the second protein fused to a second handle comprising a modified C-terminus intein (IC) of GP41-1 fused at its C-terminal to a β9 peptide when the β10 is fused to the modified IN, or to the β10 peptide when the β9 peptide is fused to the modified IN. Interaction between the first and second proteins reconstitutes the IN and IC into the GP41-1 that induces splicing of the reconstituted GP41-1 from the first handle and the second handle, ligating the first and the second proteins and arranging the β10 peptide and β9 peptide in a fused tandem.

The present application relates to a bifunctional fusion protein targeting CCR5 and gp41 and its application in the preparation of anti-human immunodeficiency virus drugs, and belongs to the technical field of biological medicine. The present application provides a bifunctional fusion protein targeting CCR5 and gp41, wherein the bifunctional fusion protein comprises: a fusion protein obtained by connecting a polypeptide 2P23 to the N terminus and / or C terminus of the light chain and / or heavy chain of an antibody PRO 140 or a PRO 140 mutant through a connecting peptide; or a fusion protein obtained by connecting a tag to the N terminus and / or C terminus of the above-mentioned fusion protein. The novel bifunctional fusion protein constructed in the present application not only overcomes the limitation that the original PRO 140 antibody is invalid for CXCR4 tropic strains, but also significantly improves the inhibitory activity and broad spectrum for CCR5 tropic strains, and has a higher drug resistance barrier.

This invention belongs to the fields of molecular biology and in vitro diagnostics, specifically relating to a method and kit for multiplex isothermal nucleic acid amplification based on a Gp41-Gp59 ​​fusion helicase protein and a UvsX-UvsY recombinant system. The method includes: providing an engineered helicase fusion protein comprising a Gp41 hexamer helicase domain derived from bacteriophage T4 and a Gp59 loading factor domain derived from bacteriophage T4, covalently linked by a (GGGGS)n linker sequence; providing a recombinase engine comprising a UvsX recombinase and a UvsY loading factor; running the helicase engine and recombinase engine in parallel in the same reaction system to amplify template nucleic acid under isothermal conditions of 37-45°C; and providing a kit containing the above components. This invention achieves synergistic amplification using a dual-engine system, offering advantages such as high sensitivity, ability to amplify long fragments, and support for multiplex detection.